Veru

VERU · NASDAQ

$2.38+$0.07 (+3.03%)TodayMarket closed · Oct 20, 7:58 PM ET

Prev close $2.31

Latest news

Press releaseSep 8, 8:17 AM ETGlobe Newswire
Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines’ RASONQUE™) Resistant Pancreatic Cancer into a Planned Phase 2 Clinical Trial
Press releaseSep 2, 8:30 AM ETGlobe Newswire
Veru to Participate in Fireside Chat at the 2026 Cantor Global Healthcare Conference
Press releaseAug 10, 6:30 AM ETGlobe Newswire
Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress
Press releaseAug 4, 8:30 AM ETGlobe Newswire
Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss
Press releaseAug 3, 8:30 AM ETGlobe Newswire
Veru to Report Fiscal 2026 Third Quarter Financial Results on August 10th
Press releaseJul 30, 8:30 AM ETGlobe Newswire
Veru to Participate in Fireside Chat at the Canaccord Genuity's 46th Annual Growth Investors Conference
Press releaseJul 27, 8:10 AM ETGlobe Newswire
Veru Announces Full Enrollment for Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
Press releaseJul 7, 8:30 AM ETGlobe Newswire
Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day
NewsMay 13, 8:50 AM ET
Transcript: Veru Q2 2026 Earnings Conference Call
NewsMay 13, 7:11 AM ET
Earnings Scheduled For May 13, 2026
Press releaseMay 13, 6:30 AM ETGlobe Newswire
Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress
NewsFeb 11, 6:11 AM ET
Earnings Scheduled For February 11, 2026
NewsFeb 10, 3:02 PM ET
A Look at Veru's Upcoming Earnings Report
NewsDec 17, 6:11 AM ET
Earnings Scheduled For December 17, 2025
NewsDec 16, 9:02 AM ET
A Look Ahead: Veru's Earnings Forecast
NewsDec 16, 7:42 AM ETAvi Kapoor
Top Wall Street Forecasters Revamp Veru Expectations Ahead Of Q4 Earnings
NewsDec 15, 10:54 AM ETErica Kollmann
Top Stocks With Earnings This Week: Micron, FuelCell, Carnival and More
NewsOct 30, 1:07 PM ET
12 Health Care Stocks Moving In Thursday's Intraday Session
NewsOct 30, 8:08 AM ET
12 Health Care Stocks Moving In Thursday's Pre-Market Session
NewsSep 25, 11:23 AM ETVandana Singh
Eli Lilly Ends Bimagrumab Obesity Study Weeks After Launch
Press releaseAug 11, 4:01 PM ETBusiness Wire
Laxxon Medical Announces Successful Product Development Milestone with Novel Oral Modified-Release Formulation of Veru's Enobosarm, Utilizing Laxxon's SPID®-Technology
NewsAug 11, 2:03 PM ET
A Look Ahead: Veru's Earnings Forecast
NewsMay 28, 12:11 PM ETVandana Singh
Veru's Enobosarm Shows Muscle In Wegovy Combo Trial
NewsMay 8, 4:33 AM ET
Earnings Scheduled For May 8, 2025
NewsMay 7, 4:07 PM ET
A Peek at Veru's Future Earnings
NewsJan 27, 1:56 PM ETAvi Kapoor
S&P 500 Falls Over 100 Points; Dada Nexus Shares Spike Higher
NewsJan 27, 12:05 PM ETAvi Kapoor
Dow Edges Higher; AT&T Posts Upbeat Earnings
NewsJan 27, 10:34 AM ETVandana Singh
Veru Shares Tumble Despite Enobosarm's Lean Muscle Preservation Breakthrough
NewsJan 27, 9:43 AM ETAvi Kapoor
Nasdaq Dips 3%; Chicago Fed National Activity Index Rises In December
Press releaseAug 6, 8:45 AM ETGlobe Newswire
Rapid Advancements of Innovative Antiviral – COVID-19 Drugs Generating Major Growth in Global Antiviral Drugs Market

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines’ RASONQUE™) Resistant Pancreatic Cancer into a Planned Phase 2 Clinical Trial

Veru to Participate in Fireside Chat at the 2026 Cantor Global Healthcare Conference

Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress

Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss

Veru to Report Fiscal 2026 Third Quarter Financial Results on August 10th

Veru to Participate in Fireside Chat at the Canaccord Genuity's 46th Annual Growth Investors Conference

Veru Announces Full Enrollment for Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day

Transcript: Veru Q2 2026 Earnings Conference Call

Earnings Scheduled For May 13, 2026

Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress

Earnings Scheduled For February 11, 2026

A Look at Veru's Upcoming Earnings Report

Earnings Scheduled For December 17, 2025

A Look Ahead: Veru's Earnings Forecast

Top Wall Street Forecasters Revamp Veru Expectations Ahead Of Q4 Earnings

Top Stocks With Earnings This Week: Micron, FuelCell, Carnival and More

12 Health Care Stocks Moving In Thursday's Intraday Session

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Eli Lilly Ends Bimagrumab Obesity Study Weeks After Launch

Laxxon Medical Announces Successful Product Development Milestone with Novel Oral Modified-Release Formulation of Veru's Enobosarm, Utilizing Laxxon's SPID®-Technology

A Look Ahead: Veru's Earnings Forecast

Veru's Enobosarm Shows Muscle In Wegovy Combo Trial

Earnings Scheduled For May 8, 2025

A Peek at Veru's Future Earnings

S&P 500 Falls Over 100 Points; Dada Nexus Shares Spike Higher

Dow Edges Higher; AT&T Posts Upbeat Earnings

Veru Shares Tumble Despite Enobosarm's Lean Muscle Preservation Breakthrough

Nasdaq Dips 3%; Chicago Fed National Activity Index Rises In December

Rapid Advancements of Innovative Antiviral – COVID-19 Drugs Generating Major Growth in Global Antiviral Drugs Market